Asia
Hitachi, Ltd. has entered into an agreement to provide Centro Nazionale di Adroterapia Oncologica with its proton therapy system.
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
Fundraising will support the expansion of Hummingbird Bioscience’s discovery pipeline and rapid development of its portfolio of targeted antibody therapeutics
Eisai Co., Ltd. announced that the latest information on its in-house discovered and developed eribulin mesylate will be presented during the 42nd San Antonio Breast Cancer Symposium.
The analysis found 13 key problems, but one of the most relevant is that the stated purpose of the research—which is also under attack—did not occur.
ACCIPIO® AI-powered tools assess non-contrast head CT images for intracranial hemorrhage prioritization and provide slice-level annotation
The 12th Clinical Trials on Alzheimer’s Disease conference kicks off today. One of the big stories, which will be presented on Thursday, December 5, is detailed results from Biogen’s Phase III clinical trials of aducanumab.
New certification demonstrates commitment to the highest standards of data protection across the company’s operations, systems, and products
Participating at IDF Congress 2019, Busan, to Engage with Key Stakeholders
The merger is an effort on the part of Astellas to strengthen its genetic medicine and gene therapy business.
PRESS RELEASES